Literature DB >> 24944148

Apnea as a complication of intravenous immunoglobulin therapy in a neonate.

Ashok Kumar1, Rishi Kapoor, Sriparna Basu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24944148     DOI： 10.1007/s12098-014-1509-1

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN： 0019-5456            Impact factor:   1.967


× No keyword cloud information.
  4 in total

Review 1.  Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn.

Authors:  R Gottstein; R W I Cooke
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-01       Impact factor: 5.747

Review 2.  Intravenous immunoglobulin: adverse effects and safe administration.

Authors:  Hedi Orbach; Uriel Katz; Yaniv Sherer; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

3.  Therapy with intravenous immunoglobulins: complications and side-effects.

Authors:  Matthias Wittstock; Reiner Benecke; Uwe K Zettl
Journal:  Eur Neurol       Date:  2003       Impact factor: 1.710

4.  A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network.

Authors:  A A Fanaroff; S B Korones; L L Wright; E C Wright; R L Poland; C B Bauer; J E Tyson; J B Philips; W Edwards; J F Lucey
Journal:  N Engl J Med       Date:  1994-04-21       Impact factor: 91.245
  4 in total
  1 in total

1.  International guidelines regarding the role of IVIG in the management of Rh- and ABO-mediated haemolytic disease of the newborn.

Authors:  Lani Lieberman; Enrico Lopriore; Jillian M Baker; Rachel S Bercovitz; Robert D Christensen; Gemma Crighton; Meghan Delaney; Ruchika Goel; Jeanne E Hendrickson; Amy Keir; Denise Landry; Ursula La Rocca; Brigitte Lemyre; Rolf F Maier; Eduardo Muniz-Diaz; Susan Nahirniak; Helen V New; Katerina Pavenski; Maria Cristina Pessoa Dos Santos; Glenn Ramsey; Nadine Shehata
Journal:  Br J Haematol       Date:  2022-04-12       Impact factor: 8.615
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.